Research Papers:
Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2761 views | HTML 2966 views | ?
Abstract
Lacey M. Litchfield1, Abir Mukherjee1, Mark A. Eckert1, Alyssa Johnson1, Kathryn A. Mills1, Shawn Pan1, Viji Shridhar2, Ernst Lengyel1 and Iris L. Romero1
1 Department of Obstetrics and Gynecology, Gordon Center for Integrative Science, University of Chicago, Chicago, Illinois, USA
2 Department of Laboratory Medicine and Experimental Pathology, Mayo Clinic Cancer Center, Rochester, Minnesota, USA
Correspondence to:
Iris L. Romero, email:
Keywords: ovarian cancer, metformin, hyperglycemia, glycolysis, c-Myc
Received: April 20, 2015 Accepted: June 04, 2015 Published: June 19, 2015
Abstract
Increasing interest in repurposing the diabetic medication metformin for cancer treatment has raised important questions about the translation of promising preclinical findings to therapeutic efficacy, especially in non-diabetic patients. A significant limitation of the findings to date is the use of supraphysiologic metformin doses and hyperglycemic conditions in vitro. Our goals were to determine the impact of hyperglycemia on metformin response and to address the applicability of metformin as a cancer therapeutic in non-diabetic patients. In normoglycemic conditions, lower concentrations of metformin were required to inhibit cell viability, while metformin treatment in hyperglycemic conditions resulted in increased glucose uptake and glycolytic flux, contributing to cell survival. Mechanistically, maintenance of c-Myc expression under conditions of hyperglycemia or via gene amplification facilitated metabolic escape from the effects of metformin. In vivo, treatment of an ovarian cancer mouse model with metformin resulted in greater tumor weight reduction in normoglycemic vs. hyperglycemic mice, with increased c-Myc expression observed in metformin-treated hyperglycemic mice. These findings indicate that hyperglycemia inhibits the anti-cancer effects of metformin in vitro and in vivo. Furthermore, our results suggest that metformin may elicit stronger responses in normoglycemic vs. hyperglycemic patients, highlighting the need for prospective clinical testing in patients without diabetes.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4556